More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$407947452
EPS
-0.03
P/E ratio
--
Price to sales
2.03
Dividend yield
--
Beta
1.841018
Previous close
$2.13
Today's open
$2.14
Day's range
$2.01 - $2.14
52 week range
$1.38 - $3.47
show more
CEO
William M. Greenman
Employees
275
Headquarters
Concord, CA
Exchange
NASDAQ Global Market
Shares outstanding
201954184
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Cerus: 3 Key Takeaways for Long-Term Investors
Phase III REDeS study met primary efficacy and safety endpoints. Kit sales represented 90% of third-quarter fibrinogen complex product shipments.
The Motley Fool • Nov 3, 2026

Cerus Corporation (CERS) Q3 2026 Earnings Call Transcript
Cerus Corporation ( CERS ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants Timothy Lee - Head of Investor Relation Vivek Jayaraman - CEO, President & Director Kevin Green - VP of Finance & CFO Conference Call Participants Colin Clark - TD Cowen, Research Division Mark Massaro - BTIG, LLC, Research Division William Bonello - Craig-Hallum Capital Group LLC, Research Division Gabrielle Ingoglia - Cantor Fitzgerald & Co., Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Cerus Corp. Q3 2026 Earnings Conference Call.
Seeking Alpha • Nov 3, 2026

Cerus' blood-safety system meets main goal in late-stage trial
Cerus' blood-safety system meets main goal in late-stage trial
Reuters • Nov 2, 2026

Cerus Q3 Earnings Call Highlights
Cerus NASDAQ: CERS reported third-quarter product revenue growth of 10% year over year and reaffirmed its 2026 revenue outlook, while also announcing positive top-line results from its Phase III RedeS study of pathogen-reduced red blood cells.
MarketBeat • Nov 3, 2026

Cerus Corporation Announces Third Quarter 2026 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the third quarter ended September 30, 2026, and provided a business update. "Our solid performance in Q3 builds upon a strong first half of 2026 and increases our confidence as we approach year-end,” said Vivek Jayaraman, Cerus's president and chief executive officer. “Continued growth from our IFC business, core platelet franchise and international INT 200 rollout strengthens our foundation.
Business Wire • Nov 2, 2026

Cerus Corporation Announces Positive Topline Results from Phase 3 RedeS Trial of the INTERCEPT Blood System for Red Blood Cells
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced positive topline results from the Phase 3 RedeS (NCT03037164) trial. “Over the past decade, pathogen reduction technology has become an integral component of the blood safety toolkit. The topline results from the RedeS study reinforce the potential to extend this established paradigm to red blood cell transfusions,” said Ross M. Fasano, MD, Professor of Pathology & Laboratory Medicine and Hematology at Emory.
Business Wire • Nov 2, 2026

Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2026 financial results will be released on Monday, November 2, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relati.
Business Wire • Oct 19, 2026

Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that it will host an industry workshop on the implementation and real-world experience with INTERCEPT Platelets and INTERCEPT Fibrinogen Complex, or IFC*, at the 2026 Association for the Advancement of Blood and Biotherapies (AABB) Annual Meeting, taking place in Atlanta, Georgia from October 17 through October 19. The AABB Annual Meeting attracts healthcare professionals, scientists, and other experts from aroun.
Business Wire • Oct 14, 2026

Cerus: This Blood-Safety Underdog Should Be Earning More Respect
Cerus (CERS) is pivoting toward higher-value therapeutic products while reducing its research cost burden, aided by substantial government funding. Q2 2026 results signal an inflection point: product revenue grew 10%, operating expenses fell 7%, and adjusted EBITDA more than tripled year-over-year. Management raised full-year revenue guidance for the second time this year, now projecting $229–231 million, reflecting growing confidence in commercial momentum.
Seeking Alpha • Aug 18, 2026

Cerus Q2 Earnings Call Highlights
Cerus NASDAQ: CERS reported second-quarter product revenue growth of 10% year over year and raised the low end of its 2026 product revenue outlook, citing demand for its INTERCEPT blood-safety products in North America and overseas.
MarketBeat • Jul 30, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Cerus Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.